Provided by Tiger Trade Technology Pte. Ltd.

Hillhouse Capital Holdings

4,991.71
-8.6104-0.17%
Number of Gainers:30
Number of Losers:33
Number of Flat:2
PE:- -
High:5,006.00
Open:5,000.08
Low:4,951.59
Close:5,000.32
Volume:301.07M
Turnover:31.20B
Market Cap:8.91T
Float Cap:8.45T

Loading ...

TSMC Shares Hit Record High on Terafab Project Talks

Stock News
·
Oct 05

Uber Settles Sexual Assault Lawsuit Before Trial, Bloomberg Reports

MT Newswires Live
·
Oct 05

Uber call volume above normal and directionally bullish

TIPRANKS
·
Oct 05

Analysts Are Bullish on Top Healthcare Stocks: Liquidia Technologies (LQDA), Kodiak Sciences (KOD)

TIPRANKS
·
Oct 05

Wall Street Analysts Are Bullish on Top Technology Picks

TIPRANKS
·
Oct 05

New Buy Rating for Apple (AAPL), the Technology Giant

TIPRANKS
·
Oct 05

Will Square Seller Sync Change Apple (AAPL) Narrative

Simply Wall St.
·
Oct 05

Snowflake to host Snowflake Expedition 2026

TIPRANKS
·
Oct 05

Big Tech Pays Triple Overtime to Keep Working Through Holidays

Deep News
·
Oct 05

Snowflake to Host Expedition 2026 Virtual Event Featuring Satya Nadella Keynote Chat

Reuters
·
Oct 05

Keurig DR Pepper Reveals 2027 Beverage Innovation Ahead of Nacs Show

THOMSON REUTERS
·
Oct 05

Foresight to Present at the LD Micro 20th Annual Main Event Conference

GlobeNewswire
·
Oct 05

BridgeBio Says Interim Analysis of BBP-418 Showed Individuals Reaching Normal Levels on Limb-Girdle Muscular Dystrophy Markers

MT Newswires Live
·
Oct 05

DoorDash Unit Deliveroo Partners with Coco Robotics to Launch UK Robot Deliveries

Reuters
·
Oct 05

BofA Securities Adjusts Affiliated Managers Group Price Target to $504 From $488

MT Newswires Live
·
Oct 05

Coco Robotics and Deliveroo Announce Exclusive Partnership to Scale Robot Deliveries Across the UK

THOMSON REUTERS
·
Oct 05

BridgeBio Says Phase 3 Fortify Data Show BBP-418 Normalizes HS Troponin I in Lgmd2i/r9 Patients by Month 12

Reuters
·
Oct 05

Bbp-418 Demonstrates Potential to be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

THOMSON REUTERS
·
Oct 05

BridgeBio Pharma - Bbp-418 Met All Primary and Secondary Endpoints at 12-Month Interim Phase 3 Fortify Trial

THOMSON REUTERS
·
Oct 05

BridgeBio Pharma - 100% of Bbp-418-Treated Lgmd2i/R9 Patients Normalize Hs Troponin I at Month 12

THOMSON REUTERS
·
Oct 05